Medicare's GLP-1 Bridge Program: Access Challenges for Patients with Health Conditions
In January, Jeff La Marca received a prescription for Zepbound, a popular weight loss medication, but he was unable to afford the $750 monthly cost. In July, Medicare introduced an 18-month pilot program known as the GLP-1 Bridge, which allows some enrollees to access GLP-1 medications for just $50 a month. La Marca was hopeful this program would make the drug affordable for him. However, his application was denied due to his severe obstructive sleep apnea, a condition that excludes him from the program despite his significant health risks associated with obesity, including a BMI of 42, a history of heart surgery, and prediabetes. La Marca expressed his frustration, stating, "I’m livid. I’m at risk for stroke, and yet I can’t get it."
The GLP-1 Bridge program aims to address the long-standing issue of affordability for GLP-1 medications, which are often inaccessible even to those with health insurance. Federal regulations have historically prevented Medicare from covering drugs prescribed solely for weight loss, making the introduction of this program significant. It offers coverage for three GLP-1 medications, including Wegovy and the KwikPen formulation of Zepbound, to patients with a body mass index (BMI) of 35 or higher. Those with a BMI of 27 to 34 may qualify if they have additional health conditions like prediabetes or cardiovascular disease.
However, a critical stipulation of the program is that the $50 price applies only to individuals using the drug solely for weight loss. Patients with qualifying medical conditions, such as Type 2 diabetes or obstructive sleep apnea, must revert to their Medicare Part D plans, which can result in copays ranging from $200 to $600 per month. Juliette Cubanski, who leads the Program on Medicare Policy at KFF, noted that the program was designed to assist those who cannot obtain GLP-1 coverage through Part D but would benefit from these medications for weight management.
The financial implications for Medicare depend on enrollment numbers. Cubanski estimates that 3.8 million people may qualify, and if a quarter participate, the program could cost Medicare approximately $3.3 billion. If three-quarters enroll, costs could escalate to $10 billion. Expanding the program to include an additional 5.9 million people already eligible for GLP-1 coverage through Part D would further increase expenditures.
Despite the program's initial success, with most prior authorization requests completed quickly, many patients like La Marca are left struggling to afford their prescriptions. Primary care physician Taylor Lacy highlighted that the program inadvertently excludes patients with the most pressing medical needs, as they often face high copays after navigating the complex prior authorization process.
As La Marca continues to seek affordable access to his prescribed GLP-1 medication, he reflects on the barriers he faces. "This is now my quest, because it’s my only chance to improve my health," he said, emphasizing the urgency of his situation and the challenges posed by the current healthcare system.




